Spatial Genomics Inc v. 10X Genomics Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Spatial Genomics, Inc. (Delaware) and The California Institute of Technology (California)
  • Defendant: 10X Genomics, Inc. (Delaware)
  • Plaintiff's Counsel: Ashby & Geddes
• Case Identification: Spatial Genomics, Inc. v. 10X Genomics, Inc., 1:26-cv-00963, D. Del., 08/05/2026
• Venue Allegations: Venue is alleged to be proper in the District of Delaware because the Defendant, 10X Genomics, Inc., is a Delaware corporation and therefore resides in the district.
• Core Dispute: Plaintiffs allege that Defendant's Xenium spatial biology platform infringes five patents related to sequential fluorescence in situ hybridization (seqFISH) technology for identifying and mapping biomolecules in cells and tissues.
• Technical Context: The technology enables spatial genomics, a field focused on creating high-resolution maps of gene expression and other molecular activity within the native context of tissues, which is significant for research in oncology, neuroscience, and developmental biology.
• Key Procedural History: Plaintiff Spatial Genomics, Inc. (SG) is the exclusive licensee of the asserted patents, which are assigned to Plaintiff The California Institute of Technology (Caltech). The complaint alleges that Defendant 10X Genomics, Inc. (10x) had pre-suit knowledge of the patent family through business discussions, a 10x-owned patent that cites one of the asserted patents, and deposition testimony from separate litigation involving a third party.

Case Timeline

Date	Event
2013-04-30	Earliest Priority Date for all Asserted Patents
2019-10-29	U.S. Patent No. 10,457,980 Issues
2021-06-01	Alleged business discussions between 10x and SG
2021-07-30	Alleged date of 10x's knowledge of '980 Patent
2022-10-18	U.S. Patent No. 11,473,129 Issues
2022-12-08	10x commercially launches its Xenium platform
2024-04-24	Deposition of Prof. Long Cai in prior litigation, allegedly establishing 10x's knowledge of '129 Patent
2025-05-20	U.S. Patent No. 12,305,224 Issues
2026-04-14	U.S. Patent No. 12,601,007 Issues
2026-04-18	10x announces Atera platform
2026-05-19	U.S. Patent No. 12,630,868 Issues
2026-08-04	Alleged date SG notified 10x of infringement
2026-08-05	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,457,980 - "Multiplex Labeling of Molecules by Sequential Hybridization Barcoding," issued October 29, 2019 ('980 Patent)

The Invention Explained

• Problem Addressed: The patent's background section identifies a need for improved methods of profiling nucleic acids within cells (Compl. ¶13). It notes that existing in situ technologies are often inefficient or limited in the number of targets they can analyze simultaneously, for example due to the limited number of distinct fluorescent colors available ('980 Patent, col. 1:26-34; '980 Patent, col. 1:61-66).
• The Patented Solution: The invention provides a method of sequential barcoding using multiple rounds of hybridization and imaging. In each round, the sample is contacted with a set of detectably labeled probes, imaged to record the signal locations, and then the probes are removed ('980 Patent, abstract). The sequence of signals (e.g., colors) detected at a particular location over multiple rounds creates a unique temporal barcode for the nucleic acid at that spot, allowing many different molecules to be identified and differentiated using only a few detectable labels ('980 Patent, col. 2:5-12; '980 Patent, FIG. 1).
• Technical Importance: This sequential barcoding method enables highly multiplexed in situ analysis, allowing researchers to profile a large number of different transcripts or DNA loci within a single cell while preserving spatial information ('980 Patent, col. 2:5-12).

Key Claims at a Glance

• The complaint asserts independent claims 1 and 2 (Compl. ¶28).
• Essential elements of independent claim 1 include:
  • A method of providing a unique molecular barcode for each unique nucleic acid molecule in a sample.
  • Performing a first contacting step with a first plurality of detectably labeled oligonucleotides.
  • Imaging the sample after the first contacting step.
  • Performing a second contacting step with a second plurality of detectably labeled oligonucleotides, where the second plurality differs from the first in its labeling.
  • Imaging the sample after the second contacting step.
  • Optionally repeating the contacting and imaging steps with new pluralities of oligonucleotides.
  • The sequence of steps produces a unique molecular barcode for each nucleic acid molecule.
• The complaint also asserts dependent claim 9 and reserves the right to assert other claims (Compl. ¶31; Compl. ¶72).

U.S. Patent No. 11,473,129 - "Multiplex Labeling of Molecules by Sequential Hybridization Barcoding," issued October 18, 2022 ('129 Patent)

The Invention Explained

• Problem Addressed: As a continuation of the application leading to the '980 Patent, the '129 patent addresses the same problem: the limitations of prior art methods for profiling nucleic acids, which are described as being inefficient, costly, or not sufficiently scalable for high-throughput analysis ('129 Patent, col. 1:35-39; '129 Patent, col. 1:52-64).
• The Patented Solution: The patent describes a method for generating a barcode for target nucleic acids, specifically RNA, in a sample. The method involves repeated cycles of contacting the sample with different pluralities of detectably labeled oligonucleotides and imaging the sample after each contact step ('129 Patent, abstract). This process allows each target RNA to be described by a unique barcode based on the sequence of detected signals, differentiating it from other RNA molecules in the sample ('129 Patent, col. 2:14-25; '129 Patent, FIG. 1).
• Technical Importance: The technology provides a high-throughput method for spatially resolved RNA profiling within cells, overcoming the multiplexing limits of traditional fluorescence in situ hybridization (FISH) ('129 Patent, col. 2:5-13).

Key Claims at a Glance

• The complaint asserts the sole independent claim, claim 1 (Compl. ¶34).
• Essential elements of independent claim 1 include:
  • A method comprising contacting a sample containing target RNA with a first plurality of detectably labeled oligonucleotides.
  • Imaging the sample after the first contacting step.
  • Repeating the contacting and imaging steps with new pluralities of detectably labeled oligonucleotides.
  • The repeated steps result in the target RNA being described by a barcode that can differentiate it from other target nucleic acids.
• The complaint asserts multiple dependent claims, including 2, 8, 12, 28, and 52, and reserves the right to assert others (Compl. ¶36; Compl. ¶82).

U.S. Patent No. 12,305,224 - "Multiplex Labeling of Molecules by Sequential Hybridization Barcoding," issued May 20, 2025 ('224 Patent)

• Technology Synopsis: This patent, from the same family, claims a method for barcoding transcripts within a cell using sequential hybridization rounds. It specifically recites the use of "intermediate oligonucleotides" that bind to the target transcript and, in turn, are targeted by the detectably labeled probes, adding a layer to the detection chemistry to solve problems of inefficiency in prior art methods ('224 Patent, col. 1:49-61; '224 Patent, claim 1).
• Asserted Claims: Independent claims 1 and 11 (Compl. ¶39).
• Accused Features: The accused Xenium platform's method of performing successive rounds of fluorescent probe hybridization, imaging, and probe removal to generate an optical signature for gene transcripts (Compl. ¶17; Compl. ¶92).

U.S. Patent No. 12,601,007 - "Multiplex Labeling of Molecules by Sequential Hybridization Barcoding," issued April 14, 2026 ('007 Patent)

• Technology Synopsis: This patent claims a sequential barcoding method that includes a preliminary step of amplifying the target nucleic acids within the cell before the hybridization and imaging cycles begin. This amplification is intended to increase the signal from the target molecules, addressing challenges in detecting low-abundance transcripts ('007 Patent, col. 2:7-12; '007 Patent, claim 1).
• Asserted Claims: Independent claims 1 and 18 (Compl. ¶45).
• Accused Features: The Xenium platform's alleged use of "circularizable probes specific to target transcripts followed by enzymatic amplification to create a target for fluorescent probe hybridization" (Compl. ¶16; Compl. ¶102).

U.S. Patent No. 12,630,868 - "Multiplex Labeling of Molecules by Sequential Hybridization Barcoding," issued May 19, 2026 ('868 Patent)

• Technology Synopsis: This patent claims a broader method of sequential barcoding for a plurality of target molecules that can be "nucleic acids, proteins, or combination thereof." This extends the patented barcoding technique beyond nucleic acids to also enable the profiling of proteins, allowing for multi-modal molecular analysis in the same sample ('868 Patent, abstract; '868 Patent, claim 2).
• Asserted Claims: Independent claims 1 and 2 (Compl. ¶50).
• Accused Features: The Xenium platform's barcoding method, particularly in conjunction with 10x's sale of "protein subpanels" for use with the instrument (Compl. ¶20; Compl. ¶112).

III. The Accused Instrumentality

Product Identification

• The complaint identifies the "Accused Products" as the 10x Genomics Xenium platform, which includes the Xenium Analyzer instrument, associated software (Xenium Explorer), and consumables such as reagents and gene panels (Compl. ¶14; Compl. ¶15). The complaint also notes a newly announced "Atera" platform, which has been used by researchers on an early access basis (Compl. ¶25).

Functionality and Market Context

• The Xenium platform is a spatial genomics system designed to create spatial maps of gene expression within tissue at cellular resolutions (Compl. ¶15).
• Its technical operation is described as performing "successive rounds of fluorescent probe hybridization, imaging, and probe removal to generate an optical signature for each gene transcript" (Compl. ¶17).
• The complaint specifically alleges that the Xenium platform "uses circularizable probes specific to target transcripts followed by enzymatic amplification to create a target for fluorescent probe hybridization" (Compl. ¶16).
• Plaintiffs position the Accused Products as direct competitors to their own GenePS platform in the "nascent spatial genomics market" and allege that 10x launched its platform commercially before SG did (Compl. ¶11; Compl. ¶15; Compl. ¶64; Compl. ¶65).

IV. Analysis of Infringement Allegations

The complaint references claim-chart exhibits that are not provided. The following tables are constructed based on the narrative infringement allegations in the complaint.

No probative visual evidence provided in complaint.

'980 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method of providing a unique molecular barcode for each unique nucleic acid molecule in a plurality of nucleic acid molecules in a sample, comprising the steps of: (a) performing a first contacting step that involves contacting the sample with a first plurality of detectably labeled oligonucleotides...	The Xenium Analyzer instrument contacts a tissue sample with fluorescently labeled probes that target RNA transcripts.	¶16	col. 6:29-41
(b) imaging the sample after the first contacting step...	The instrument uses microscope images to detect the location of each fluorescent probe in the tissue.	¶16	col. 7:8-11
(c) performing a second contacting step that involves contacting the sample with a second plurality of detectably labeled oligonucleotides...wherein the second plurality differs from the first plurality...	The instrument performs "successive rounds" of probe hybridization; after the first round, the probe is removed, and a subsequent round of hybridization is performed with probes that create a new optical signal.	¶16; ¶17	col. 7:12-38
(d) imaging the sample after the second contacting step...	The instrument captures images of the tissue after each successive round of probe hybridization.	¶17	col. 7:39-42
(e) optionally repeating the contacting and imaging steps, each time with a new plurality of detectably labeled oligonucleotides...wherein steps (a) to (e) produce a unique molecular barcode for each unique nucleic acid molecule in the sample.	The "Successive rounds of fluorescent probe hybridization, imaging and removal creates an optical signature that reveals the identity of the RNA at a location," which is alleged to be the claimed barcode.	¶16; ¶17	col. 7:43-56

Identified Points of Contention:

• Scope Question: A central question will be whether the "optical signature" generated by the Xenium platform (Compl. ¶16) constitutes a "unique molecular barcode" as required by the claim. This may turn on evidence of whether the accused system can distinguish and barcode individual nucleic acid molecules in situ.
• Technical Question: The claim requires that the second plurality of probes "differs from the first plurality" in its labeling. A point of contention may be whether the specific chemistry and sequence of probes used in the successive rounds of the Xenium process meets this claim limitation.

'129 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method, comprising steps of: (a) contacting a sample comprising a plurality of target nucleic acids with a first plurality of detectably labelled oligonucleotides...wherein all target nucleic acids comprise RNA;	The Xenium Analyzer instrument is used to detect RNA targets in a tissue section by contacting the sample with fluorescent probes.	¶16	col. 10:1-8
(b) imaging the sample after the first contacting step so that interaction of the detectably labelled oligonucleotides with their target nucleic acid is detected;	Microscope images are captured on the Xenium Analyzer to detect the location of the hybridized probes.	¶16	col. 10:9-12
(c) repeating the contacting and imaging steps, each time with a new plurality of detectably labelled oligonucleotides, so that a target nucleic acid in the sample is described by a barcode...	The instrument performs "successive rounds of fluorescent probe hybridization, imaging and removal" to generate an "optical signature" that allegedly functions as the claimed barcode.	¶16; ¶17	col. 10:13-22

Identified Points of Contention:

• Technical Question: The complaint mentions the assertion of dependent claim 12, which requires interaction via "intermediate oligonucleotides" (Compl. ¶36). The infringement allegation centers on the Xenium platform's use of "circularizable probes...followed by enzymatic amplification to create a target for fluorescent probe hybridization" (Compl. ¶16). The court will need to determine if this amplification-based, two-part targeting scheme constitutes the use of "intermediate oligonucleotides" as taught in the patent.
• Scope Question: The claim requires that the repeating steps result in the target nucleic acid being "described by a barcode." A potential point of dispute is whether the "optical signature" generated by the accused system (Compl. ¶16) meets the patent's definition of a barcode that can uniquely identify and differentiate targets.

V. Key Claim Terms for Construction

Term: "unique molecular barcode" ('980 Patent, claim 1)

Context and Importance

• This term defines the final output of the claimed method. Infringement will depend on whether the "optical signature" generated by the accused Xenium platform (Compl. ¶16) can be construed as a "unique molecular barcode." Practitioners may focus on this term because it is central to the novelty of the invention and the core of the infringement allegation.

Intrinsic Evidence for Interpretation

• Evidence for a Broader Interpretation: The specification describes the barcode as a "temporal sequence of dyes" ('980 Patent, col. 9:53-54), which could support interpreting the term to cover any sequence of detected signals over time.
• Evidence for a Narrower Interpretation: The claim's use of "unique" and "molecular" may support a narrower construction requiring single-molecule resolution and the ability to distinguish each individual molecule from others in the sample. The patent's examples show specific color sequences corresponding to specific genes (e.g., "mRNA 1: Yellow-Blue-Yellow") which could be argued to set a standard for what constitutes a barcode under the patent ('980 Patent, col. 9:44-47).

Term: "intermediate oligonucleotides" ('224 Patent, claim 1; '129 Patent, claim 12)

Context and Importance

• The definition of this term is critical because the complaint alleges the Xenium platform uses "circularizable probes" and "enzymatic amplification" to create a target for the final fluorescent probe (Compl. ¶16), a process Plaintiffs will likely argue meets this limitation.

Intrinsic Evidence for Interpretation

• Evidence for a Broader Interpretation: The specification describes a general architecture where an intermediate oligonucleotide has an "overhang" for a "bridge probe" to bind, a structure that could be argued to broadly cover any multi-part probe system ('129 Patent, col. 17:31-37).
• Evidence for a Narrower Interpretation: The patent's figures (e.g., '129 Patent, FIG. 21) depict a specific structure of a "Bridging Strand" and an "Intermediate Probe Strand." A defendant could argue that the term requires this specific, non-amplified, two-part structure, and that the accused system's use of enzymatic amplification creates a technically distinct mechanism.

VI. Other Allegations

Indirect Infringement

• The complaint alleges both induced and contributory infringement.
  • Inducement: Allegations are based on 10x making and selling the Accused Products and providing "detailed instructions" and encouragement to its customers and end users on how to use the products in a way that directly infringes the asserted patents (Compl. ¶74; Compl. ¶84; Compl. ¶94; Compl. ¶104; Compl. ¶114).
  • Contributory: Allegations are based on 10x selling components of the Accused Products that are "especially made or especially adapted for use in a manner that infringes" and are not staple articles of commerce suitable for substantial non-infringing use (Compl. ¶75; Compl. ¶85; Compl. ¶95; Compl. ¶105; Compl. ¶115).

Willful Infringement

• The complaint alleges willful infringement based on both pre- and post-suit knowledge. Pre-suit knowledge is alleged to arise from business discussions between the parties beginning on or around June 1, 2021 (Compl. ¶66); a 10x-owned patent that incorporates the '980 Patent by reference (Compl. ¶57); and a deposition of an inventor in prior, separate litigation involving 10x (Compl. ¶58; Compl. ¶61). Post-suit knowledge is alleged from a notice letter and the filing of the complaint itself (Compl. ¶73; Compl. ¶83).

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of claim scope and construction: can the "optical signature" generated by the 10x Xenium platform be construed as the "unique molecular barcode" required by the claims? The case may turn on the level of precision, uniqueness, and single-molecule resolution required by the patent's definition of a "barcode" versus what is achieved by the accused system.
• A key evidentiary question will be one of technical mechanism: does the accused system's use of "circularizable probes...followed by enzymatic amplification" (Compl. ¶16) meet the claim limitations requiring "amplification" (in the '007 patent) or the use of "intermediate oligonucleotides" (in the '129 and '224 patents)? This will require a detailed technical comparison of the specific chemistries and processes involved.
• A third central question will concern damages and willfulness: the complaint makes specific factual allegations of pre-suit knowledge, citing a 10x-owned patent and prior litigation testimony. The strength of this evidence will be critical in determining whether Plaintiffs can prove willful infringement, which could expose the Defendant to an award of enhanced damages.